

November 20, 2018



## CymaBay Therapeutics to Participate in Upcoming Investor Conferences

NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming investor conferences: the Piper Jaffray 30<sup>th</sup> Annual Healthcare Conference, the Evercore ISI HealthCONx Conference, and the BMO Prescriptions for Success Conference.

### ***Piper Jaffray 30<sup>th</sup> Annual Healthcare Conference***

Date: Tuesday, November 27  
Time: 12:00pm Eastern Time  
Location: Lotte New York Palace Hotel

### ***Evercore ISI HealthCONx Conference***

Date: Wednesday, November 28  
Time: 9:05am Eastern Time  
Location: Boston Harbor Hotel

### ***BMO Prescriptions for Success Conference***

Date: Wednesday, December 12  
Time: 11:40am Eastern Time  
Location: Mandarin Oriental NYC

To access a live webcast and subsequent archived recording of each presentation, please visit the "Events" section on the CymaBay website at <http://ir.cymabay.com/events>.

### **About CymaBay**

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR $\delta$  agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently conducting a Phase 3 study of seladelpar for PBC and a Phase 2b study of seladelpar for NASH.

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

**Contact:**

Hans Vitzthum

LifeSci Advisors, LLC

617-535-7743

[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.